NKGen Releases Additional Phase 1 Data on Alzheimer's Candidate

Monday, 25 March 2024, 22:54

The latest phase 1 data from NKGen Biotech reveals encouraging advancements in cognitive functions and biomarkers among individuals undergoing SNK01, their innovative NK cell therapy. The findings indicate significant progress towards potential Alzheimer's treatment.
https://store.livarava.com/13da7c47-eafb-11ee-aeb7-63fd8ea994ba.jpg
NKGen Releases Additional Phase 1 Data on Alzheimer's Candidate

NKGen Announces Promising Data Update on Alzheimer's Candidate

NKGen Biotech has released additional phase 1 data showcasing improvements in cognitive functions and biomarkers in patients who received SNK01, their NK cell therapy.

Key Points:

  • Promising Results: The data indicates notable cognitive enhancements and positive changes in biomarkers.
  • Significant Progress: The findings suggest a potential breakthrough in Alzheimer's treatment.

Overall, NKGen's research shows promising results in advancing Alzheimer's therapies.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe